IRLAB Therapeutics AB
STO:IRLAB A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (4.8), the stock would be worth kr1.72 (21% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.9 | kr1.42 |
0%
|
| 3-Year Average | 4.8 | kr1.72 |
+21%
|
| 5-Year Average | 5.3 | kr1.92 |
+35%
|
| Industry Average | 1.7 | kr0.6 |
-58%
|
| Country Average | 2.2 | kr0.79 |
-44%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
|
IRLAB Therapeutics AB
STO:IRLAB A
|
120.6m SEK | 3.9 | -1.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 30.3 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 6.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 5.8 | 27.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 7.1 | 20.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 5.2 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 6 | 11.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 1.7 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 6.3 | 16.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.2 |
| 70th Percentile | 3.7 |
| Max | 283.3 |
Other Multiples
IRLAB Therapeutics AB
Glance View
IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-02-28. The company focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The firm possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The firm operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
